سعر ابو-ميفلوكين 250 مجم 8 اقراص 2022

Mefloquine 250 mg tablets (antimalarial for treatment and prophylaxis of malaria), pack of 8 tablets; Apotex Inc. (Canada), Egyptian Pharmex.

• Treatment of mild to moderate acute malaria caused by mefloquine-susceptible P. falciparum (chloroquine-susceptible and -resistant strains) or P. vivax (follow with an 8-aminoquinoline such as primaquine to prevent P. vivax relapse).Population: Adults and paediatric patients >=6 monthsDailyMed (U.S. National Library of Medicine)
• Prophylaxis of P. falciparum and P. vivax malaria, including chloroquine-resistant P. falciparum.Population: Adults and childrenDailyMed (U.S. National Library of Medicine)

• Prophylaxis: vomiting was most frequent (3%); dizziness, syncope and extrasystoles in <1%. During treatment, adverse effects may be indistinguishable from malaria symptoms.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to mefloquine, related compounds (quinine, quinidine) or excipients. Must not be prescribed for prophylaxis in active or recent depression, generalised anxiety disorder, psychosis, schizophrenia or other major psychiatric disorders, or a history of convulsions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: neuropsychiatric adverse reactions that can persist after discontinuation; do not use for prophylaxis in major psychiatric disorders; discontinue prophylaxis if psychiatric or neurological symptoms occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Psychiatric symptoms (anxiety, paranoia, depression, hallucinations, psychosis, suicidal ideation) and neurological symptoms (dizziness/vertigo, tinnitus, loss of balance, possibly permanent) may occur; may increase convulsion risk in epilepsy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Potentially fatal QTc prolongation with halofantrine or ketoconazole (avoid during and within 15 weeks after mefloquine); ECG abnormalities with quinine or quinidine.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Halofantrine; ketoconazoleRisk of potentially fatal QTc prolongation; do not give with mefloquine or within 15 weeks of the last mefloquine dose (ketoconazole also raises mefloquine exposure).DailyMed (U.S. National Library of Medicine)
• Quinine, quinidine and other drugs affecting cardiac conduction (antiarrhythmics, beta-blockers, calcium channel blockers, antihistamines, tricyclic antidepressants, phenothiazines)May produce ECG abnormalities or contribute to QTc prolongation.DailyMed (U.S. National Library of Medicine)
• Anticonvulsants (valproic acid, carbamazepine, phenobarbital, phenytoin)Mefloquine may lower anticonvulsant levels and seizure control; monitor levels and adjust dose.DailyMed (U.S. National Library of Medicine)

• Published data in pregnant women showed no increase in teratogenic risk or adverse pregnancy outcomes after treatment or prophylaxis; animal studies showed teratogenic effects. Use in pregnancy only if clearly needed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Excreted in human milk in small amounts (3-4% in a small study); use caution in nursing women.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Mefloquine: Antimalarial blood schizonticide active against erythrocytic stages of Plasmodium species; exact mechanism not known (US label).